Drug intelligence / Profile preview

LY2881835

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

LY2881835 is a potent and selective small molecule agonist of the G protein-coupled receptor 40 (GPR40), also known as free fatty acid receptor 1 (FFAR1). It was developed as an oral antihyperglycemic agent for the treatment of type 2 diabetes mellitus. The drug acts by stimulating GPR40, which enhances glucose-dependent insulin secretion from pancreatic beta cells and increases GLP-1 secretion, leading to improved glycemic control. Preclinical studies demonstrated that LY2881835 provides immediate and durable reductions in blood glucose levels in rodent models of both early- and late-stage type 2 diabetes. Clinical development reached phase I trials but was discontinued for type 2 diabetes[1][4][7].

Other names: UNII-LAD0ZG7FFOUNII-LAD-0ZG7FFOUNII-LAD 0ZG7FFO

Targets

FFAR1 (Free fatty acid receptor 1)

Beyond the preview

Go deeper on LY2881835.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY2881835.

Explore the full profile